经皮冷冻消融治疗硬纤维瘤病:英国某中心的初步经验
该研究报告英国某专科癌症中心10例患者共13次经皮冷冻消融治疗硬纤维瘤病的初步经验,重点描述技术、安全性和疗效。大肿瘤(长轴>10 cm)较小肿瘤辐射剂量更高、使用冷冻探针更多、残留未消融肿瘤比例更高。除1例短暂桡神经麻痹外不良事件轻微,8/10例患者获得症状改善,完全消融者均出现症状缓解且无重复治疗、复发或需全身治疗。
要点
- 大肿瘤(长轴>10 cm)较小肿瘤辐射剂量更高、冷冻探针更多、残留未消融肿瘤比例更高。
- 除1例短暂桡神经麻痹外,不良事件均为轻微。
- 完全消融者均出现症状缓解,研究期间无重复治疗、复发或需全身治疗。
核心结论
- 经皮冷冻消融治疗有症状的硬纤维瘤病是一种可重复的技术,毒性低且短暂,一到两次治疗即可获得有意义的缓解;在可能的情况下,消融冰球应完全覆盖硬纤维瘤。
研究设计与样本
- 单中心初步经验报告,2019年2月至2021年8月共10例患者(8例女性,中位年龄51岁,IQR 42-69岁)接受13次经皮冷冻消融;患者由专科癌症医院多学科肿瘤委员会会议筛选;比较小肿瘤与长轴>10 cm大肿瘤的辐射剂量、手术时长和冷冻探针数量;采用多种标准评估MRI反应,并计算与肿瘤科门诊临床反应评估的百分比一致性。
关键影像表现/征象
- 大肿瘤(长轴>10 cm)较小肿瘤辐射剂量更高(2012 ± 1012 vs 1076 ± 519 mGy·cm,p=0.048)。
- 大肿瘤较小肿瘤使用冷冻探针更多(13 ± 7 vs 4 ± 2,p=0.009)。
- 大肿瘤较小肿瘤更易出现残留未消融肿瘤(38 ± 37% vs 7.5 ± 10%,p=0.045)。
- 所有进展均发生在消融区之外。
临床应用与阅片要点
- 在可能的情况下,消融冰球应完全覆盖硬纤维瘤。
- 大肿瘤(长轴>10 cm)手术时需注意辐射剂量更高、冷冻探针更多、残留未消融肿瘤比例更高。
局限性
- 原文标题及目的部分自述为「初步经验」(initial experience)。
- 研究期间有3例患者在临床症状获益后平均393天后开始全身治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
AIM: To report the first UK experience of cryoablation in desmoid fibromatosis (DF) with particular focus on technique, safety, and efficacy.
MATERIALS AND METHODS: Patients were selected at multidisciplinary tumour board meetings at a specialist cancer hospital. Radiation dose, procedure duration, and number of cryoprobes were compared for small versus large tumours (>10 cm long axis). Response at magnetic resonance imaging (MRI) was evaluated using different criteria, and percentage agreement with clinical response as assessed in oncology clinic calculated.
RESULTS: Thirteen procedures were performed in 10 patients (eight women, median age 51 years, IQR 42-69 years) between February 2019 and August 2021. Procedures for large tumours had higher radiation dose (2,012 ± 1,012 versus 1,076 ± 519 mGy·cm, p=0.048) used more cryoprobes (13 ± 7 versus 4 ± 2, p=0.009), and were more likely to have residual unablated tumour (38 ± 37% versus 7.5 ± 10%, p=0.045). Adverse events were minor apart from one transient radial nerve palsy. Eight of 10 patients had symptomatic benefit at clinical follow-up (median 353 days, IQR 86-796 days), and three started systemic therapy mean 393 days later. All patients who had complete ablation demonstrated symptomatic response, with no instances of repeat treatment, recurrence, or need for systemic therapy during the study period. All progression occurred outside ablation zones.
CONCLUSION: Cryoablation for symptomatic DF is a reproducible technique with low, transient toxicity, where one or two treatments can achieve a meaningful response. Where possible, the ablation ice ball should fully cover DF tumours.
引用
- Johnston, Alves, Messiou, et al. Percutaneous cryoablation for desmoid fibromatosis: initial experience at a UK centre. Clin Radiol. 2022. PMID: 35850865. doi:10.1016/j.crad.2022.06.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。